Main Article Content

Multiple Myeloma


D.B. Bernard
S.R. Lynch
T.H. Bothwell
W.R. Bezwoda
K. Stevens
G. Shulman

Abstract

The results of the use of melphalan in 52 patients with multiple myeloma have been analysed.  The median survival of the whole group of patients was 30 months, and of those with renal insufficiency only 12,5 months. Bence-lones proteinuria was also a poor prognostic finding,. but only because of its association with renal failure. Patients with Bence-Jones proteinuria and normal renal function had a median survival of 41 months. Responsiveness to therapy by criteria based on those of the Chronic Leukemial Multiple Myeloma Task Force could be assessed in 25 patients. Dramatic symptomatic relief occurred in all but one of the responsive patients, but in only one-fifth of those who did not respond to therapy.

S. Afr. Med. J., 48, 1026 (1974).

Journal Identifiers


eISSN: 2078-5135
print ISSN: 0256-9574